Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-450 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | Low dose ABT-450 capsule and ritonavir capsules (reference). |
| B | ACTIVE_COMPARATOR | Low dose ABT-450 SDD Tablet Form 1 and ritonavir capsules (test 1) |
| C | ACTIVE_COMPARATOR | Low dose ABT-450 SDD Tablet Form 2 and ritonavir capsules (test 2). |
| D | ACTIVE_COMPARATOR | High dose ABT-450 capsule and ritonavir capsules (reference). |
| E | ACTIVE_COMPARATOR | High dose ABT-450 SDD Tablet Form 1 or 2 and ritonavir capsule (test) |
| 1 | ACTIVE_COMPARATOR | ABT-450/ritonavir |
| 2 | PLACEBO_COMPARATOR | Placebo for ABT-450/placebo for ritonavir |
| Name | Type | Description |
|---|---|---|
| ABT-450 | DRUG | Low dose ABT-450 / ritonavir see Arm Description for more information |
| ritonavir | DRUG | ritonavir see Arm Description for more information |
| Placebo for ABT-450 | DRUG | capsule, QD or BID, 14 days |
| Placebo for ritonavir | DRUG | capsule, QD or BID, 14 days |
Inclusion Criteria * Overall healthy subjects * Non-childbearing potential females included Exclusion Criteria * Positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab * Clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic...
Top 20 of 28 competitors
ABT-450 is an investigational small molecule being studied for the treatment of HCV Infection and for use in Healthy volunteers. It is being developed by Abbott Laboratories (ticker: ABT). The drug is currently in Phase 1 clinical development and is not yet approved.
ABT-450 is being developed by Abbott Laboratories, a company traded under the ticker ABT. The drug is an investigational small molecule in Phase 1 clinical trials for HCV Infection and Healthy volunteer studies.
ABT-450 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for HCV Infection and in Healthy volunteers, with all trials completed.
ABT-450 has been studied in three completed Phase 1 trials. These include NCT00909311, which evaluated the effect of food on the drug with ritonavir in 8 participants, and NCT00931281, which assessed pharmacokinetics with ritonavir in 38 participants. A third trial, NCT01091649, studied bioavailability of tablet formulations in 40 healthy adults.
ABT-450 is often studied in combination with ritonavir, a pharmacokinetic enhancer. Clinical trials NCT00909311 and NCT00931281 both evaluated ABT-450 when given with ritonavir. However, ABT-450 itself is the active drug being investigated, and ritonavir is used to boost its levels.